- Home
- DVAX vs HASI Comparison
DVAX vs HASI Comparison
Compare DVAX & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVAX | HASI |
|---|---|---|
| Founded | 1996 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 4.2B |
| IPO Year | 2004 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DVAX | HASI |
|---|---|---|
| Price | $11.25 | $33.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $26.50 | ★ $39.56 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 5.16% |
| EPS Growth | N/A | ★ 27.54 |
| EPS | N/A | ★ 2.32 |
| Revenue | ★ $330,514,000.00 | $99,644,000.00 |
| Revenue This Year | $24.63 | $187.33 |
| Revenue Next Year | $15.85 | $16.20 |
| P/E Ratio | ★ N/A | $14.07 |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $21.98 |
| 52 Week High | $14.63 | $34.54 |
Technical Indicators
Market Signals| Indicator | DVAX | HASI |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 49.82 |
| Support Level | $10.63 | $32.45 |
| Resistance Level | $11.02 | $33.72 |
| Average True Range (ATR) | 0.25 | 0.70 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 80.30 | 11.25 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.